<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04033861</url>
  </required_header>
  <id_info>
    <org_study_id>rhBNP-myocardium</org_study_id>
    <nct_id>NCT04033861</nct_id>
  </id_info>
  <brief_title>Early rhBNP on Myocardial Remodeling and Reperfusion in Patients With STEMI</brief_title>
  <official_title>Prospective Observational Clinical Study：The Impact of Early rhBNP on Myocardial Remodeling and Reperfusion in Patients With ST-segment Elevation Myocardial Infarction After Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study intends to evaluate the efficacy of early rhBNP on myocardial remodeling and
      reperfusion in patients with ST-segment elevation myocardial infarction after percutaneous
      coronary intervention
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As prospectively observational study，it brings anterior acute myocardial infarct patients
      from 2018 JAN. to 2019 JAN, whose predefined time between symptom onset and percutaneous is
      not more than 12 hours. The door-to-balloon time, present to balloon time and first medical
      contact-to-balloon time will be documented. ECG in FMC and 90min after PCI also will be
      record. Patients assigned to the rhBNP group will receive intravenous rhBNP before PCI，and
      the variety of heart rate and blood pressure will be record. Routinely evaluation of
      corrected TIMI frame counting（CTFC）, TIMI myocardial perfusion frame counting and TIMI
      myocardial perfusion grade(TMPG).Blood tests including BNP, CK-MB and CRP are measured at
      admission and6, 12, 24, 48 hours after PCI. Both Cardiovascular magnetic imaging and
      echocardiography will be applied in Day 30 and 12 months. The composite endpoint is incidence
      of all-cause mortality, reinfarct, stroke and target vessel revascularization at
      hospitalization and follow-up. Principally patients are prevented from any drug affecting
      microcirculation (GPIIb/IIa receptor agonist, vascular dilation drug, etc.), otherwise it is
      necessary, which should be documented.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compound endpoints of epicardium and endocardium perfusion</measure>
    <time_frame>90min after infarct related artery revascularization</time_frame>
    <description>Both the TIMI and TMPG score reach 3 immediately after PCI, besides ST resolution≥70% at 90min after PCI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ST-segment Resolution</measure>
    <time_frame>90 mins after PCI</time_frame>
    <description>Resolution of the initial sum of ST-segment elevation ≥ 70%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wall motion score index (WMSI) and LVEF by echocardiography</measure>
    <time_frame>Day 1, 3, 7, 30 and 12 month after PCI</time_frame>
    <description>Echocardiographic index includes WMSI and LVEF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIMI Flow Grade (TFG)</measure>
    <time_frame>One mins after PCI</time_frame>
    <description>TIMI Flow Grade (TFG)assesses flow in the epicardial arteries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIMI Frame Count (CTFC)</measure>
    <time_frame>One mins after PCI</time_frame>
    <description>CTFC is a continuous measurement assessing flow in the epicardial arteries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIMI Myocardial Perfusion Grade (TMPG)</measure>
    <time_frame>One mins after PCI</time_frame>
    <description>TMPG is an angiographic measure of myocardial perfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIMI Myocardial Perfusion Frame Count (TMPFC)</measure>
    <time_frame>One mins after PCI</time_frame>
    <description>TMPFC is a novel method to standardize and quantify myocardial perfusion by timing the filling and washout of contrast in the myocardium using cine-angiographic frame-counting. Briefly, the first frame of TMPFC was defined as the frame that clearly demonstrated the first appearance of myocardial blush beyond the IRA (F1). The last frame of TMPFC was then defined as the frame where contrast or myocardial blush disappeared (F2). TMPFC is F2-F1 frame counts at a filming rate of 15 frames/sec, or (F2-F1)×2 frame counts at the corrected filming rate of 30 frames/sec</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR imaging</measure>
    <time_frame>Day 1, 3, 7, 30 and 12 month after PCI</time_frame>
    <description>CMR imaging will be collected using a 3.0-Tesla-scanner (Achieva, Philips Healthcare, The Netherlands) under electrocardiogram-triggered gating in School Shanghai Jiaotong University school of medicine RenJi hospital.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>hemodynamic adverse related to rhBNP</measure>
    <time_frame>72 hour since rhBNP administration</time_frame>
    <description>low perfusion sign, and Noninvasive systolic blood pressure is below 90mmHg with or without diastolic blood pressure below 60mmHg, Excluding other reason.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">352</enrollment>
  <condition>ST Segment Elevated Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>rhBNP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour after randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhBNP</intervention_name>
    <description>rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.</description>
    <arm_group_label>rhBNP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients are eligible for enrollment if they are suspected as anterior myocardial infarct
        (anterior myocardial infarct is defined as persistent chest pain for 30 mins at least, with
        ST-segment elevation of at least 0.2 mV in two or more contiguous precordial leads) within
        12 hours after onsets of symptom, and no contraindication for rhBNP. The coronary
        angiography (CAG) proves left anterior descending (LAD) as culprit vessel, which was
        totally or nearly occlusion with TIMI 0-1 grade and resulted in TIMI 3 grade after PCI.

        Exclusive criteria:

          1. Killips grade III-IV.

          2. unstable hemodynamic; with A-V block or atrial fibrillation;

          3. Contraindication of magnetic resonance, such as history of metal, ICD or paceman
             implant;

          4. history of myocardial infarct;

          5. pregnancy or breeding;

          6. combined with other serious diseases: severe renal dysfunction (creatinine
             clearance&lt;30ml/min;), liver failure, neutropenia, thrombocytopenia, acute
             pancreatitis；

          7. life expectancy≤12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Pu, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong Univers</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Pu, MD,PhD</last_name>
    <phone>86-21-68383477</phone>
    <email>pujun310@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ren Ji Hospital Afflited to School of Medicine, Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jun Pu, MD,PHD</last_name>
      <phone>86-21-68383477</phone>
      <email>pujun310@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Ding S, Pu J, Qiao ZQ, Shan P, Song W, Du Y, Shen JY, Jin SX, Sun Y, Shen L, Lim YL, He B. TIMI myocardial perfusion frame count: a new method to assess myocardial perfusion and its predictive value for short-term prognosis. Catheter Cardiovasc Interv. 2010 Apr 1;75(5):722-32. doi: 10.1002/ccd.22298.</citation>
    <PMID>19960517</PMID>
  </reference>
  <reference>
    <citation>Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009 Dec 22;120(25):2577-85. doi: 10.1161/CIRCULATIONAHA.109.912550. Epub 2009 Nov 18.</citation>
    <PMID>19923168</PMID>
  </reference>
  <reference>
    <citation>Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley R, Marble SJ, McCabe CH, Van De Werf F, Braunwald E. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000 Jan 18;101(2):125-30.</citation>
    <PMID>10637197</PMID>
  </reference>
  <reference>
    <citation>van 't Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation. 1998 Jun 16;97(23):2302-6.</citation>
    <PMID>9639373</PMID>
  </reference>
  <reference>
    <citation>Chinese Society of Cardiology of Chinese Medical Association; Editorial Board of Chinese Journal of Cardiology. [Guideline of non-ST segment elevation acute coronary syndrome]. Zhonghua Xin Xue Guan Bing Za Zhi. 2012 May;40(5):353-67. Chinese.</citation>
    <PMID>22883082</PMID>
  </reference>
  <reference>
    <citation>Kidambi A, Mather AN, Motwani M, Swoboda P, Uddin A, Greenwood JP, Plein S. The effect of microvascular obstruction and intramyocardial hemorrhage on contractile recovery in reperfused myocardial infarction: insights from cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2013 Jun 27;15:58. doi: 10.1186/1532-429X-15-58.</citation>
    <PMID>23806080</PMID>
  </reference>
  <reference>
    <citation>Roe MT, Ohman EM, Maas AC, Christenson RH, Mahaffey KW, Granger CB, Harrington RA, Califf RM, Krucoff MW. Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. J Am Coll Cardiol. 2001 Jan;37(1):9-18. Review.</citation>
    <PMID>11153779</PMID>
  </reference>
  <reference>
    <citation>Pu J, Shan P, Ding S, Qiao Z, Jiang L, Song W, Du Y, Shen J, Shen L, Jin S, He B. Gender differences in epicardial and tissue-level reperfusion in patients undergoing primary angioplasty for acute myocardial infarction. Atherosclerosis. 2011 Mar;215(1):203-8. doi: 10.1016/j.atherosclerosis.2010.11.019. Epub 2010 Nov 26.</citation>
    <PMID>21176835</PMID>
  </reference>
  <reference>
    <citation>Pu J, Ding S, Shan P, Qiao Z, Song W, Du Y, Shen J, Jin S, He B. Comparison of epicardial and myocardial perfusions after primary coronary angioplasty for ST-elevation myocardial infarction in patients under and over 75 years of age. Aging Clin Exp Res. 2010 Aug;22(4):295-302. doi: 10.3275/6711. Epub 2009 Dec 1.</citation>
    <PMID>20009495</PMID>
  </reference>
  <reference>
    <citation>Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449.</citation>
    <PMID>21670242</PMID>
  </reference>
  <reference>
    <citation>Shen LH, Wan F, Shen L, Ding S, Gong XR, Qiao ZQ, Du YP, Song W, Shen JY, Jin SX, Pu J, Yao TB, Jiang LS, Li WZ, Zhou GW, Liu SW, Han YL, He B. Pharmacoinvasive therapy for ST elevation myocardial infarction in China: a pilot study. J Thromb Thrombolysis. 2012 Jan;33(1):101-8. doi: 10.1007/s11239-011-0657-7.</citation>
    <PMID>22094974</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 24, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2019</study_first_posted>
  <last_update_submitted>November 5, 2019</last_update_submitted>
  <last_update_submitted_qc>November 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ST Segment Elevated Myocardial Infarction</keyword>
  <keyword>rhBNP</keyword>
  <keyword>cardiac magnetic resonance</keyword>
  <keyword>Microvascular disease</keyword>
  <keyword>ventricular remodeling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

